MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

79.15 2.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

76.81

Max

79.39

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-252M -129M
Pardavimai	-295M 157M
Pelno marža	-82.062
Darbuotojai	1,069
EBITDA	-254M -103M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+24.35% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-18

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	730M 12B
Ankstesnė atidarymo kaina	76.89
Ankstesnė uždarymo kaina	79.15

Naujienos nuotaikos

By Acuity

50%

159 / 361 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-20 23:43; UTC

Rinkos pokalbiai

Gold Consolidates; May Face Technical Correction -- Market Talk

2026-01-20 23:42; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

2026-01-20 23:41; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

2026-01-20 23:29; UTC

Rinkos pokalbiai

RBA Rate Hike in February Would Be a Painful One -- Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-20 23:26; UTC

Rinkos pokalbiai

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

2026-01-20 22:45; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

2026-01-20 22:44; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

2026-01-20 22:43; UTC

Įsigijimai, susijungimai, perėmimai

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

2026-01-20 22:27; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

2026-01-20 22:25; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

2026-01-20 22:21; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

2026-01-20 22:20; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

2026-01-20 22:19; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

2026-01-20 22:18; UTC

Uždarbis

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

2026-01-20 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Live Events Are Boosting Retention, Co-CEO Says

2026-01-20 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

2026-01-20 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

2026-01-20 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

2026-01-20 22:11; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

2026-01-20 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

2026-01-20 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

2026-01-20 22:07; UTC

Įsigijimai, susijungimai, perėmimai

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

2026-01-20 22:06; UTC

Uždarbis

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

2026-01-20 22:00; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

ESG Roundup: Market Talk

2026-01-20 21:50; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

24.35% į viršų

12 mėnesių prognozė

Vidutinis 94.92 USD 24.35%

Aukščiausias 110 USD

Žemiausias 77 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

159 / 361 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.